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1. Introduction
Engineered nanomaterials (ENMs) can be defined as “a natural, 
incidental or manufactured material containing particles, in 
an unbound state or as an aggregate or as an agglomerate and 
where, for 50% or more of the particles in the number size dis-
tribution, one or more external dimensions is in the size range 
1–100 nm.”[1] While much is made of which definition of an 
ENM should be used,[2] the one defined by the European Union 
(EU) in 2011[1] is most apt even today, as it considers the devel-
opment of ENMs into products, and how they may interact with 
other entities, and not simply just the raw materials for focus by 
scientific research only.[3] This is particularly important, since 
ENM are advantageous for numerous usages, including indus-
trial, consumer, medical, and environmental applications, all 
of which will lead to elevated human exposures.[4] Their mass 
application to such areas drives the total value of the nanotech-
nology industry to the $1 trillion level, and beyond.[5] To achieve 
this, significantly large ENM quantities must be produced on 
a yearly basis. To put it into perspective, it has been calculated 
that the total amount of titanium dioxide ENMs, often found 
in many cosmetics[6] (e.g., suncreams, moisturizers) and has 
received increased attention recently from a regulatory con-
text,[7] are produced at over 45 000 tons per year.[8] Meanwhile, 
carbon nanotubes, proposed for use as a construction material 
and found in car tires,[9] which also seemingly receive constant 
To elucidate the impact of human exposure to engineered nanomaterials, 
advanced in vitro models are a valid non-animal alternative. Despite 
significant gains over the last decade, implementation of these approaches 
remains limited. This work discusses the current state-of-the-art and how 
future developments can lead to advanced in vitro models better supporting 
nano-hazard assessment.
negative attention due to their physical 
characteristics,[10] are estimated to be pro-
duced at only >1200 tons per year.[8] Thus, 
considering the fact that there are thou-
sands of ENMs already used in indus-
trial applications,[11] and thousands more 
in production,[12] human exposure is an 
inevitable outcome of nanotechnology.[13] 
Yet, to fully deduce the opportunities that 
nanotechnology-orientated applications 
and methods can have towards human health, understanding 
of the potential risks posed must be gained.[14]
The field of nanoparticle toxicology,[15] or as it is known now-
adays as “nanosafety,”[16] is a constantly evolving discipline. In 
the 1990s, the first articles were only just being published in 
terms of nanoparticle toxicology,[17] leading to the sub-discipline 
of particle and fiber toxicology, that is, “nanotoxicology,” being 
coined.[18] Further, and only over a decade ago, the field was 
focused upon determining which specific physico-chemical 
characteristics should be most prominently defined in order to 
understand structure–activity relationships.[19] To the present 
day, research continues to increase almost daily in order to fully 
elucidate both the potential opportunities and risks posed by 
ENMs.[20,21] How ENM risk is determined however, is a topic of 
constant debate and heightened research activity, as well as con-
comitant to the research actually assessing ENM risk.[22] Notably, 
enhanced scrutiny is currently focused towards which biological 
systems are most apt to elucidate the human health impact of 
inevitable exposure to ENMs.[23] Numerous questions remain as 
to the relevance, validity, and morality of using invasive animal 
experimentation. Further, with the EU legislative ban upon in 
vivo research within the cosmetics industry,[24,25] as well as the 
recent announcement of the United States Environmental Pro-
tection Agency to ban all animal testing by 2035, a heightened 
emphasis is nowadays given towards alternative approaches, 
namely, in vitro approaches. Thus, having an (advanced) alter-
native biological-based model system that can re-create the key 
components of a complete organism has become the ultimate 
scientific desire.[23] Despite the great strides taken in the past 
few years towards this objective there remains a plethora of 
questions, most importantly which alternative models, if any, 
have the potential to meet this requirement for not only basic 
research, but also for industrial and regulatory hazard charac-
terization and risk assessment purposes.[26,27]
2. Motivation to Create Valid Alternatives
Although it is considered, still, the gold standard for toxicology 
testing,[28] in vivo approaches remain questionable in terms of 
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their relevance towards fully understanding the hazard impli-
cations towards human health.[29] There have been plentiful 
examples throughout history in this regard. For example, the 
drug “Thalidomide” is inert within rodents, yet is significantly 
detrimental to the human fetus.[30] This highlights the dif-
ferences within the reproduction systems/cycles of different 
mammals, and that any form of in vivo approaches to deduce 
impacts of drugs/xenobiotics upon the reproduction system/
cycle must be specific to the species.[31] This is also true of other 
organs, for example, the lungs. In a canine, the lung tissue has 
microscopic pores throughout it, which is not the case in the 
normal human lung.[32] The surface area of a rodents’ lungs, 
while mathematically can be correlated to humans, are dif-
ferent structurally.[33] Further, primates (e.g., rhesus monkey) 
have significant differences in the structure (i.e., number of 
lobes) compared to the human lung,[34] and therefore absolute 
direct comparisons are not possible. Thus, it is questionable as 
to their relevance as a surrogate of the human lung to deter-
mine the impact of inhaling particulates.[35] Further, while the 
cell types within a rodents’ lungs (e.g., mouse), at the macro-
molecular level can be similar, when understanding the immu-
nological impact of an inhaled foreign body it has been noted 
that intra-species cells can exhibit different receptors, making it 
difficult to conclude absolute implications from classical in vivo 
research towards human health.[36] Therefore, although in vivo 
(i.e., rodents, monkeys, dogs) provide the “whole body system,” 
numerous questions remain, for example, their metabolism 
levels,[36] as to the pertinence and relevance of conducting such 
testing strategies to assess the human health implications of 
new materials, drugs, and other xenobiotics.[29]
Within the field of nanosafety however, since the EU ban 
upon animal experimentation in the cosmetic industry took 
effect,[24] the number of publications using the phrase “in vitro” 
or “alternative(s)” has increased on a yearly basis.[21] Based 
upon the decade prior to that, the number of articles, while 
increasing, was exponentially lower than after the EU ban.[21] 
This indicates that the ban upon cosmetics testing using in vivo 
systems was, to an extent, successful; however, it also highlights 
the fact that when animal experimentation was no longer a valid 
tool, it was possible to utilize an alternative approach.[37] With 
the increase in alternative models however, while initiating an 
intended reduction and refinement within in vivo approaches, 
it poses the question as to the usefulness of in vitro cell cul-
tures, and furthermore what types of cell cultures should be 
focused on in terms of any proposed replacement strategy for 
the previously widely used, invasive animal testing approach.[38]
3. Current Status and Key Points of (Advanced) In 
Vitro Systems
As previously discussed by Evans and colleagues,[39] and fur-
ther highlighted in Table 1, there are numerous different types 
of advanced in vitro systems that can be considered, spanning 
most organs of the human body.[40]
These can focus upon mammalian cell cultures that may 
be constructed as either single- or multiple-cell cultures, also 
referred to as mono- or multicellular systems, or as 3D models, 
otherwise known as “oid” cultures (e.g., organoids, sphe-
roids).[41] Beyond static cultures, in whichever geometry, also 
include more physiologically relevant systems, such as micro-
fluidic cell cultures,[39] or dynamic breathing approaches.[42] 
Interestingly, it is reported that for nearly every organ of the 
human body, these different cell culture approaches can be 
created and adopted for different experimental questions. 
However, not many have been created specifically to study the 
potential for foreign substances to cause toxicity, or even pre-
dictability of the human hazard response.[40]
Most commonly, such alternative systems focus on the use 
of cell-lines, often cancer cell-lines, due to their relatively low 
Table 1. Summary of the advantages and disadvantages of the currently available advanced in vitro systems. Adapted under the terms of the Creative 
Commons Attribution 3.0 Unported (CC BY 3.0) license.[39] Copyright 2016, The Authors, Published by Oxford University Press on behalf of The UK 
Environmental Mutagen Society.
Type of advanced in vitro system Structure/cellular construct Advantages/disadvantages
Multicellular systems Multiple (i.e., two or more) cell types cultured together, 
commonly within trans-well membrane inserts. These systems are 
indicative of a specific cellular construct of a specific tissue type 
within the human body
Enables cell-to-cell interplay representing important  
(barrier and immune) cell types relevant to target tissue
High cost, laborious nature (often needing specific expertise) 
Considered highly indicative of the specific tissue being studied
Microtissues (e.g., “oid” culture 
systems)
Cell cultures that undergo a degree of self-assembly that enables 
the formulation of geometric structure that closely resembles the 
human tissue of interest (e.g., 3D tissue-like structure (spheroid) 
of the human liver)
Allows for important cellular interplay and specific geometry  
of anatomical structure
High cost, laborious, short culture period and is unable to be 
used for certain biochemical endpoints depending upon size
Complex 3D structures Models that are commercially available resembling primary cell 
cultures/multi-tissue layer systems and are representative of 
specific tissues
Closely mimics in vivo
High cost, laborious nature (often needing specific expertise) 
Considered highly indicative of the specific tissue being studied
Micro-fluidic devices Models (often mono- and co-cultures) that are incorporated into 
bio-engineered devices allowing additional in vivo relevance to the 
in vitro approach (i.e., fluid-flow (mimicking blood-flow) and/or 
dynamic movement (mimicking breathing pattern))
High cost, requires specific expertise, and additional 
equipment (i.e., peristaltic pump)
Laborious to find optimal application of system  
with in vitro model
Provides additional and advanced in vivo characteristics  
beyond static in vitro systems
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complexity, although primary cells are also utilized. Importantly 
though, it is essential that the correct cell type is used to rep-
resent the correct organ. In many cases, it has been reported 
that cells from one organ are used to represent the same par-
ticular cell type, but in a different organ.[43] A prime example of 
this is the human umbilical endothelial cell (HUVEC). These 
are relatively inexpensive, are easy to culture, and can be used 
for multiple passages with little to no mutation shift. However, 
if used as a surrogate of lung endothelial cells, then the rele-
vance of the in vitro system becomes nonsensical. Human lung 
endothelial cells (HULECs) exist, and while they exhibit similar 
characteristics to HUVECs, they are pedantically different with 
respect to organ specificity. Thus, a key factor in the creation of 
any in vitro model is that the key organ/tissue characteristics 
are understood at the single cell type level (or 2D) prior to ini-
tiating advanced in vitro models (of any geometry). Subsequent 
confirmation of these characteristics throughout the creation of 
any advanced in vitro model is also essential. The characteristics 
monitored however, can be related to the specific cell types being 
used. For example, immune cells, the phenotype, (pro-)inflam-
matory mediator baseline, morphology, and maturation status 
would be important. Whereas a barrier cell, for example, epithe-
lial cell, the growth curve/proliferation index, barrier capacity/
membrane integrity, and monolayer morphology would be apt. 
Irrespective, how the cells culture over passage number, iden-
tification of the maximum passage number is essential for any 
cell-line used. For primary cells, the source must be similar 
(and ethically approved), but more so a continuous quality con-
trol concerning the phenotype and morphology is imperative to 
maintain consistency across cultures and time.[44] The scaffold, 
or matrix that the cells are cultured upon is also significant in 
this regard and needs to be considered in these approaches.[45]
In addition to the baseline approaches and extensive charac-
terization needed to create advanced alternative models, it is a 
common perspective that any alternative system beyond a mono-
culture has significant complexity requiring extensive training, 
increased consumable cost, and is more labor intensive. This is 
a usual misconception. The difficulty with any advanced, alter-
native model lies within the technique and characterization of 
the system (as noted above). Further, the specificity and rel-
evance of the in vitro model to the in vivo (i.e., human) organ is 
paramount. There are some examples in the literature of com-
plex multicellular systems that simply apply different cell types 
into the same dish. Human organs consist of complex, cellular 
structures creating the tissue system organ, and thus this must 
be represented as such in vitro; for example, the lung requires 
structural building of cell types, as shown in the model from 
Rothen-Rutishauser et  al.[46] This is also true of spheroid cul-
tures as well, in that the cellular architecture must be carefully 
constructed in order to allow the cellular self-assembly into the 
spherical geometry. Thus, knowledge of the anatomy and physi-
ology of the organ-type model being created in vitro is necessary. 
Most notably, many in vitro systems have been created to study 
the cell-to-cell interplay, which is the widely cited major advan-
tage of multicellular systems, as well as the role that specific cell 
types have in disease progression (e.g., fibrosis).[47] Interestingly 
though, for those systems that have been used for toxicology 
testing, it has been in the monoculture format, since these relate 
to many of the regulatory testing approaches (e.g., Organization 
for Economic Cooperation and Development (OECD) Micro-
nucleus Test that uses TK6 human B-lymphoblastoma cells).[48] 
Nonetheless, there have been studies comparing the toxico-
logical outcomes of using different cell systems (from mono-
cultures to multicellular systems) to assess their suitability of 
ENM hazard characterization. For example, in the study of Clift 
and colleagues,[49] it was observed that when comparing the co-
culture of Rothen-Rutishauser and its representative cells at the 
monoculture level, that the toxicological outcome was the same, 
but the effect level was heightened in the multicellular system 
when controlled for cellular protein levels. Thus, it is important 
to deduce the relevance of advanced in vitro systems as an alter-
native to invasive animal experimentation.
4. Relevance of In Vitro Systems to Humans
One of the key questions related to in vitro systems in gen-
eral is their relevance to the human system. While the perti-
nent, scientific research to support any answer to this question 
remains lacking, and needed. Relevance can of course be 
attributed to the systems characteristics and architecture (as 
previously described above). Yet, if we consider this further, 
many alternative in vitro systems published focus upon static 
cultures. Very few consider the notion that in the “whole 
body” in vivo approach all tissues/cells are at least impacted by 
dynamic flow—of either a liquid (i.e., liver) or air (i.e., lung).[50] 
In a study by Moore and colleagues,[51] it was reported that 
when cells were placed within a period of dynamic flow that 
their phenotype as well as transendothelial transport was signif-
icantly altered. It has also previously been noted that dynamic 
flow can change the maturation and differentiation status of 
cells in vitro.[52] Thus, this physiological parameter, while being 
vitally important to mimic a further dimension of the in vivo 
approach in vitro, seemingly creates a significant change within 
the cells compared to the static approach. There are a number 
of commercially available systems on the market, and so it 
would be essential to start to integrate such important physi-
ological factors into advanced in vitro models in general. It is 
also important to note the “organ-on-a-chip” movement that is 
increasing the complexity of model systems and allowing mul-
tiple organs models to be connected in vitro.[53] However, as 
of yet this model system has not showed anything different to 
what is seen with single cell systems under dynamic flow.
Consideration of such in vivo relevance has been considered 
with respect to lung and skin in vitro systems. For these sys-
tems, it is commonplace now to conduct ENM hazard assess-
ment using cultures at the air–liquid interface (ALI), thus rec-
reating the 1) gas-exchange region in the lower human lung,[54] 
and 2) the surface of the epidermis.[55] As regards the former 
however, understanding how dynamic movement,[56] and the 
role of lung lining fluid (i.e., surfactant)[57] has been explored 
through preliminary assessments, but knowledge in this area 
remains elementary at this moment in time. Such advances 
though, would allow lung in vitro models to take an additional 
step forward in their physiological relevance when compared to 
the in vivo situation.
When considering other organs being developed, for 
example, liver spheroids, the O2 content is important. Normally 
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they are kept in the conventional incubator environment (i.e., 
37 °C, 5% CO2, 20% O2, 75% N2). Yet, in the human liver, the 
O2 content is <2%. Thus, when approaching understanding the 
ENM impact upon the liver and using spheroids, the O2 content 
becomes extremely relevant and important in the development 
of advanced, alternative models. Such differences in the envi-
ronment that the cells are cultured within would also have an 
impact upon cellular metabolism, which would further impact 
the ENM-cell interaction. In this regard, the temperature that 
the cell cultures are kept will also impact on how ENMs interact 
with the cell system (i.e., 4  °C will inhibit any form of endo-
cytosis). On a final note in this topic, the use of cell culture 
supplements is a component often overlooked by in vitro scien-
tists. Commonly we are focused upon the overall model being 
an “alternative” system, but remain using animal products, 
that is, fetal bovine serum and animal-tested antibodies. It is 
interesting to note that we continue to culture primary human 
cells with fetal bovine serum (FBS) in our cell culture media, 
when, in fact, human serum would be more pertinent. Alas, 
the availability and cost implications of using human serum 
often result in the continued use of the more prevalent and 
cost effective FBS. However, the point is that in the attempts 
to create advantageous, alternative model systems to animal 
experimentation, it could be more productive to make small, 
specific alterations to the system, which could have a similar if 
not heightened improvement towards the in vitro model itself 
and its output.[58,59]
5. How Predictive Are In Vitro Models  
for Toxicology Testing
As previously highlighted, there have been limited advanced 
models used to assess the impact of ENMs. Further, there are 
no published reports of in vitro models being used to predict 
the human response to ENM exposure, as yet. However, this 
is the ultimate goal. In an attempt to close the knowledge gap, 
Snyder-Talkington and colleagues[60] compared an in vitro bi-
culture of epithelial and endothelial cells to a rodent model 
and observed significant differences at the gene level for (pro-)
inflammatory mediators after carbon nanotube exposure. Alas, 
this approach, while it should be applauded, highlights an 
issue that we have in this scenario. As scientists we are cre-
ating advanced models using human cells, but then comparing 
the effects of the human-based model against an animal 
system (e.g., rats, mice) to then predict a response in a human 
body. For exposures (e.g., quartz, asbestos), it is possible to 
compare to human epidemiological and toxicology studies; 
however, for ENM there is significant lack of such data, and so 
the approach of in vivo to in vitro extrapolation[61] is essential, 
especially when considering the exposure concentrations for 
the in vitro system.
With predictability in mind, it is important to highlight 
the advantageous role that adverse outcome pathway (AOP) 
approaches can have towards alternative models. By definition, 
AOPs are models that identify specific biochemical mecha-
nisms, or “key events” (KE) that are produced following a 
molecular initiating event in terms of the toxicological response 
relative to the biological system to an exposed xenobiotic.[62] 
There are a number of different AOPs currently being produced 
and tested for, the most notable being that for lung inflamma-
tion, namely, AOP173 (lung inflammation leading to fibrosis).[63] 
In theory, by enabling analysis of each KE (e.g., pro-inflamma-
tory mediator release, cell proliferation, pro-fibrotic mediator 
release, collagen production), it is possible to use an in vitro 
model to determine if it predicts the KE(s), and thus the AO. 
Recently, a study by Barosova and colleagues[64] used AOP173 to 
assess the pro-inflammatory and pro-fibrotic impacts of different 
multi-walled CNTs upon an advanced in vitro lung cell system. 
These approaches are starting to lay the foundation for the use 
of (advanced) in vitro models to predict the hazardous outcome 
of human exposure to specific xenobiotics, such as ENMs.
6. Recommendations and Future Perspective
As highlighted throughout this concept article, the approach 
of alternative model development is to provide a valuable 
assessment tool that could be easily applied in both a hazard 
screening approach and also in a regulatory setting, to better 
predict the human response following exposure to a foreign 
object, for example, ENMs, without the need to conduct inva-
sive animal testing strategies. From the previous review by 
Burden and colleagues[23,27] in which the short, medium, and 
long-term objectives are set-out for alternatives in toxicology 
testing strategies, it can be considered that the field remains 
within the short-term goals, that is, acute-phase exposures 
and response characterization, combination of several hazard 
endpoints, advanced exposure systems to cell culture models, 
and in vivo in vitro extrapolation approaches. There is progress 
towards medium-term objectives, in the sense of chronic expo-
sures and biological response analytics;[63] however, in order to 
achieve further steps towards medium-term objectives, the fol-
lowing steps should be considered:
•	 Use	 specific	 and	 relevant	 cells	 in	 the	model	 system	 being	 
formulated that most closely relate to the anatomy and 
physiology of the human organ of interest.
•	 Use	human	relevant	cell	culture	supplements	(e.g.,	serum),	
and other analytical approaches (e.g., antibodies) rather than 
animal based (in order to make it a truly animal alternative 
model).
•	 Characterize	 the	 system	 that	 is	 being	 used,	 from	 its	most	
primitive form to its most complex. In this context, there are 
two distinct levels: 1) tissue level characterization (i.e., how 
representative is the model mimicking that of the in vivo tis-
sue), and 2) hazard response level (i.e., how does the model 
respond to specific biological endpoints (i.e., oxidative stress, 
(pro-)inflammatory mediator release) following exposure to 
specific positive controls. It is important to know precisely 
what the system is and how it responds to a positive particle, 
chemical, and assay specific controls.
•	 Further,	albeit	that	the	anatomical	set-up	might	be	as	specific	
as possible, when considering the physiological relevance of 
the system, many systems currently used are static and do 
not adequately represent the key physiological components 
of the in vivo (human) system (e.g., fluid flow dynamics, tis-
sue flexing, cellular movement).
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•	 Determine	the	predictive	nature	of	the	in	vitro	model	against	
currently available in vivo and human exposure data for the 
same hazard endpoint (use of relevant AOPs are advised 
here, e.g., AOP173).
Considering these approaches, in terms of future perspec-
tive, the field must focus on
•	 Complete	 non-animal	 models/approaches,	 that	 is,	 model	
systems that are made purely of human cells and supple-
mented with non-animal supplements. Importantly though, 
that these “new” systems are then able to detect the same 
response (and effect level) as previously found with animal-
based systems (e.g., those using fetal bovine serum).
•	 Tailored	 testing	 systems	 that	 cover	 the	 range	 of	 (multiple)	
hazard endpoints required for risk assessment purposes. 
Then further developing these systems towards AOPs, as 
well as high-throughput approaches, in order to enhance the 
predictive nature of the tests coupled to the improved in vitro 
system(s).
7. Summary and Conclusion
In summary, the development of new alternative model is 
currently a fast-moving area with novel systems being intro-
duced and further improved upon at a rapid rate in order 
to understand, at the cellular level how organs develop and 
function, as well as to provide systems that could be used 
for more predictive in vitro toxicology testing, for example, 
for ENMs. Alas, while many of the advanced in vitro sys-
tems available have had at least the minimal characteriza-
tion necessary performed, and their general anatomical and 
physiological attributes relate to the human organ level, pre-
cisely how predictive these model systems are in terms of the 
human response to, for example, ENMs, is currently limited 
at best. To be precise, extremely little research has been con-
ducted in order to understand this important point, and thus 
this aspect is one of the key factors needing focus in order 
to capitalize on these new developments to promote the 3Rs 
in toxicology. Questions should start to be asked within the 
field as to whether or not many more model systems should 
be created with the intention to be predictive models for toxi-
cology testing regarding human health implications of new 
products, for example, drugs. With the plethora of models 
already available, it is arguably more pertinent to test these 
systems and determine which, if any, characteristics must 
be improved in order to obtain the closest possible, predictive 
model of the human response in vitro. While increasing the 
technology readiness levels of systems may be scientifically 
interesting, it is abundantly clear that the more complex the 
model, the more training, cost, and time is needed to conduct 
system set-up and testing. All of which are key deterrents 
for industry and legislative bodies when considering which 
testing approach to employ. Thus, understanding the useful-
ness, applicability, cost–time efficiency, and predictability of 
these advanced models are essential moving forward. Further-
more, it is also important to note that since there is a clear 
commitment towards the development and use of alternative 
methodologies within the field of nanosafety, that the incep-
tion of in vitro models using completely animal free compo-
nents, as well as biochemical assays based upon animal free 
approaches is an aspect that should be strongly considered 
from this point onwards.
Therefore, in conclusion, the field of nanosafety is on a 
good setting already in terms of utilizing the knowledge and 
expertise within the area of alternative in vitro models. In 
order to assess ENM impact upon human health, it is nec-
essary that the predictive nature of any of the plethora of 
advanced in vitro systems currently available is realized. 
Through this the overall usefulness of alternative testing strat-
egies will be determined and allow for the further creation of 
regulation and legislation for their widespread use within risk 
assessment approaches.
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